Education
About Us
Working with TipRanks
Follow Us
CNBX Pharmaceuticals (CNBX)
OTHER OTC:CNBX
CNBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume4.45K
Average Volume (3M)73.87K
Market Cap
$64.76K
Enterprise Value$1.36M
Total Cash (Recent Filing)$45.67K
Total Debt (Recent Filing)$1.40M
Price to Earnings (P/E)―
Beta0.37
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding92,511,350
10 Day Avg. Volume49,020
30 Day Avg. Volume73,871
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap20.93
Enterprise Value/Revenue3.24
Enterprise Value/Gross Profit77.16
Enterprise Value/Ebitda-0.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
CNBX FAQ
What was CNBX Pharmaceuticals’s price range in the past 12 months?
CNBX Pharmaceuticals lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is CNBX Pharmaceuticals’s market cap?
CNBX Pharmaceuticals’s market cap is $64.76K.
When is CNBX Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CNBX Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is CNBX Pharmaceuticals overvalued?
According to Wall Street analysts CNBX Pharmaceuticals’s price is currently Overvalued.
Does CNBX Pharmaceuticals pay dividends?
CNBX Pharmaceuticals does not currently pay dividends.
What is CNBX Pharmaceuticals’s EPS estimate?
CNBX Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CNBX Pharmaceuticals have?
CNBX Pharmaceuticals has 92,511,350 shares outstanding.
What happened to CNBX Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CNBX Pharmaceuticals?
Currently, no hedge funds are holding shares in CNBX
Company Description
CNBX Pharmaceuticals
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.
Salarius Pharmaceuticals
―
Quoin Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―